


1155848535252



1155848535252

location	Collection-389
summary	Interim Order 11/15/1999
author	Grace Cunningham
expiration_date	11/15/2064
max_versions	4
title	McCauley Michael F. Lic #28RI01842000 McCauley
document	Michael F. Lic #28RI01842000
keywords	
dsclass	Document
description	

8005

JOHN J. FARMER, JR.
ATTORNEY GENERAL OF NEW JERSEY
Division of Law - 5th Floor
124 Halsey Street
P.O. Box 45029
Newark, New Jersey 07101

CERTIFIED TRUE COPY

FILED

NOV 15 1999

BOARD OF PHARMACY

By: Marianne W. Greenwald
Deputy Attorney General
Tel. No. (973) 648-4738

STATE OF NEW JERSEY
DEPARTMENT OF LAW AND PUBLIC SAFETY
DIVISION OF CONSUMER AFFAIRS
STATE BOARD OF PHARMACY

IN THE MATTER OF THE SUSPENSION OR REVOCATION OF THE LICENSE OF	:	Administrative Action
	:	
MICHAEL F. McCALLLEY, R.P.	:	INTERIM ORDER
	:	
TO PRACTICE PHARMACY IN THE STATE OF NEW JERSEY	:	

This matter was opened to the State Board of Pharmacy upon the receipt of information that respondent was suspended from Morristown Hospital on September 4, 1999 after having admitted to the possession and personal use of Ativan, a Schedule IV Controlled Dangerous Substance, not pursuant to a valid prescription, and having tested positive to cocaine and opiates pursuant to a urine screen.

IT IS THEREFORE ON THIS 10th DAY OF November 1999.

- Respondent shall have his urine monitored at his own expense on a random, unannounced basis two times per week for a one month period. The urine specimens shall be performed with direct witnessing by a Board approved monitor. The initial drug screen will utilize the EMIT technique and all confirming tests and/or secondary tests will be

11/03/1999 10:10 DOCUMENT 7 197000017

performed by gas chromatographing/mass spectrometry (GC/MS). The testing procedure shall include a forensic chain of custody protocol to ensure sample integrity and to provide documentation thereof.

2. The results of all tests shall be reported directly to H. Lee Gladstein, Executive Director of the Board or his successor, or his designee in the event he is unavailable. The Board may at anytime alter or modify the manner of the testing directed herein. In the event of any such alteration or modification the Board shall give timely notice of any new testing requirement to the respondent.

3. In the event respondent is unable to appear for a scheduled urine test due to illness or other impossibility, consent to waive that day's test must be secured from the Board office. The lab monitor or monitor will not be authorized to provide consent. In addition, respondent must provide the Board with written substantiation for his inability to appear, e.g. physician's report.

4. Within 30 days from the entry of this Order, respondent shall cause the Board to receive an in-depth, current psychological valuation from a Board approved psychologist or psychiatrist.

5. Respondent shall appear before the Board for a status conference at the next regularly scheduled Board of Pharmacy meeting, on or after one month from the date of entry of this Order, at which time respondent shall demonstrate his compliance with the terms of the within Order, i.e., that all urine screens have been performed and are negative and further that he has submitted a psychological evaluation satisfactory to the Board, and has acted upon any recommendations therein.

6. Respondent shall notify the Board in writing prior to his obtaining a position in pharmacy and prior to any change in employment.

NEW JERSEY STATE BOARD OF PHARMACY

By: Richard A. Palumbo, R.P.
Richard A. Palumbo, R.P., President

I have read the within Order and understand it. I agree to be bound by its terms and hereby consent to it being entered by the New Jersey Board of Pharmacy.

Michael F. McCauley
Michael F. McCauley, R.P.